其他的研究，将进一步证明替加环素将在临床上用于治疗严重感染。
Additional studies, which will further confirm the clinical utility of tigecycline in the management of serious infections, are ongoing.
替加环素，是惠氏公司为解决新出现的、危及全球的抗生素耐药性而研制的一种甘酰胺环素类抗生素。
Tigecycline is a glycylcycline antibiotic that was developed by Wyeth in response to the worldwide threat of emerging resistance to antibiotics.
替加环素为新型抗菌甘氨环素类药物，即米诺环素的衍生物，能够克服与四环素类绝大部分相关的耐药机制。
Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetra.
NDM-1基因多存在于大肠杆菌（36份）和肺炎克雷伯杆菌（111份）中，携该基因的细菌对除替加环素和黏菌素外的抗生素普遍耐药。
NDM-1 was mostly found among Escherichia coli (36) and Klebsiella pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin.
NDM-1基因多存在于大肠杆菌（36份）和肺炎克雷伯杆菌（111份）中，携该基因的细菌对除替加环素和黏菌素外的抗生素普遍耐药。
NDM-1 was mostly found among Escherichia coli (36) and Klebsiella pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin.
应用推荐